Drug Trial Radar · NCT03304054
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Apr 18, 2018
Primary completion
Jan 31, 2020
Study completion Mar 15, 2020
Sponsor
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.
Conditions
- Myasthenia Gravis, Generalized
Interventions
Amifampridine PhosphateDrug
tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
Placebo Oral TabletDrug
tablets matching amifampridine phosphate, 3 to 4 times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test ResultsTime frame: Last day (Day 0) of the Run-in period and at the post-treatment visit (i.e., day 10 or the time point at which a patient discontinued treatment early).
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio
Univerity of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.